This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
|Articles|February 21, 2005
New AAD Board members
The following physicians have been named to the AAD Board of Directors for a four-year term: Lawrence F. Eichenfield, M.D., San Diego; Michael D. Tharp, M.D., Chicago; William D. James, M.D., Philadelphia; and Susan H. Weinkle, M.D., Bradenton, Fla.
Advertisement
The following physicians have been named to the AAD Board of Directors for a four-year term: Lawrence F. Eichenfield, M.D., San Diego; Michael D. Tharp, M.D., Chicago; William D. James, M.D., Philadelphia; and Susan H. Weinkle, M.D., Bradenton, Fla.
Advertisement
Related to this article
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
3
Alopecia Areata Awareness Month: 2026 in Review
4
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
5